BMS-214662 in Treating Patients With Solid Tumors

Inclusion Criteria: * Diagnosis of malignant solid tumor for which a standard curative therapy does not exist * Performance status - Karnofsky 70-100% * At least 6 months * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 10.0 g/dL * Bilirubin no greater than 2.0 mg/dL * AST no greater than 2 times upper limit of normal * Albumin at least 3.0 g/dL * Creatinine no greater than 1.5 mg/dL * No uncontrolled heart disease * No history of clinically significant cardiac arrhythmia that could be exacerbated by QT interval prolongation * Corrected QT interval no greater than 450 milliseconds * Must not require total parenteral nutrition * No manifestations of malabsorption syndrome due to prior surgery, gastrointestinal disease, or unknown reasons * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No signs or symptoms of acute infection requiring systemic therapy * No grade 3 or 4 neurotoxicity from prior anticancer treatment or neuropathy from any cause * No confusion, disorientation, or psychiatric illness that may preclude study * No more than 3 prior chemotherapy regimens * At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin) and recovered * No other concurrent antineoplastic agents * No concurrent hormonal anticancer therapy * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy * Prior drugs known to prolong the QT interval allowed if they can be safely discontinued for a time period equal to 4 elimination half-lives prior to administering study drug * No drugs known to prolong the QT interval during and for 24 hours after study drug * No concurrent therapy with known CYP3A4 substrates * No other concurrent investigational agents